San Giovanni Rotondo

• ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Not authorised
  2022-500535-36-00 5 Moderately to severely active ulcerative colitis
• ABTECT-Maintenance – ABX464 Treatment Evaluation for ulcerative Colitis Therapy Not authorised
  2022-500537-84-00 5 Moderately to severely active ulcerative colitis
• The Chronic kidney disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect (CAPTIVATE) Not authorised
  2024-511325-67-00 5 Chronic kidney disease
• MELFLUFEN FOR ELDERLY PATIENTS WITH RELAPSED MYELOMA Not authorised
  2024-514652-33-00 4 Relapsed Multiple Myeloma
• A clinical study of MK-7240 for the treatment of ulcerative colitis (MK-7240-001) Unknown
  2025-523766-25-00 5 Ulcerative colitis
• IntReALL BCP 2020 – International Study for Treatment of Childhood Relapsed Precursor B-cell ALL 2020 Pending
  2023-509392-17-00 5 Relapsed Acute Lymphoblastic Leukemia (ALL)
• PIrfenidone to prevent fibrOsis in ARDS. A RaNdomizEd controllEd tRial - PIONEER Pending
  2024-514355-16-01 5 Acute Respiratory Distress Syndrome (ARDS)
• Impact of early proactive therapeutic drug monitoring on the durability and efficacy of infliximab therapy in pediatric inflammatory bowel d … Pending
  2024-517759-11-00 6 Inflammatory Bowel Disease
• A PROJECT FOR TWO MULTICENTRE, PROSPECTIVE OPEN LABEL RANDOMIZED CLINICAL STUDIES TO EVALUATE THE EFFECT OF TARGETED THERAPY BASED ON KIDNEY … Pending
  2024-517861-18-00 5 Idiopathic IgA nephropathy (IgAN)
• A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy with Standard-of-Care Combination Regimens … Pending
  2024-519504-27-00 5 Relapsed Refractory Multiple Myeloma
• A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tum … Pending
  2025-521209-42-00 6 advanced colorectal cancer with wild-type RAS and right primary tumour
• A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treat … Pending
  2025-523735-19-00 5 Metastatic Microsatellite Stable Colorectal Cancer
• Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with adv … Pending
  2025-524048-36-00 5 Advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcin
• A study of cemsidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma (r/r MM) Pending
  2025-524181-26-00 4 relapsed/refractory multiple myeloma
• A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Seizures Recruiting
  2025-524038-24-00 5 2026-05-22 Focal Epilepsy
• A study to assess the efficacy and safety of empasiprubart in adults with CIDP Recruiting
  2025-520805-10-00 5 2026-03-12 Chronic inflammatory demyelinating polyneuropathy (CIDP)
• A study to investigate the effect of adding bleximenib to standard-of-care treatment with intensive chemotherapy in patients with a specific … Recruiting
  2025-522767-15-00 5 2026-01-27 Acute Myeloid Leukemia
• Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B- … Recruiting
  2025-520982-39-00 5 2025-12-09 Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-
• AFFIRM: A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Pri … Recruiting
  2024-516525-31-01 5 2025-07-14 Primary Biliary Cholangitis
• A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft-Versus-Host Disease A … Recruiting
  2024-518973-32-00 5 2025-07-03 Chronic Graft-Versus-Host Disease
• Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients with FLT3-ITD Negative AML Recruiting
  2023-507936-20-00 5 2025-05-05 Acute myeloid leukemia
• A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK10 … Recruiting
  2024-512659-19-00 10 2025-03-31 Advanced Melanoma
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C … Recruiting
  2024-515445-42-00 5 2025-03-24 Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
• Efficacy and Safety Study of Once-Daily Extended-Release Levetiracetam in Drug-resistant Focal Onset Seizures Recruiting
  2024-514499-42-00 5 2025-03-12 Refractory Partial Onset Epilepsy

Showing 1–24 of 149 trials